FCGR3A and COVID-19: To investigate associations between CD16A genotype and clinical outcomes, we conducted an analysis on 1,027 hospitalized patients with COVID-19 from the IMPACC study, a uniquely rich longitudinal dataset with extensive transcriptomic, proteomic, and clinical data.